Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.

Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB.

Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607.

2.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.

Home PD, Lam RLH, Carofano WL, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rosenstock J, Hollander PA, Gallwitz B.

Diabetes Obes Metab. 2018 Sep;20(9):2220-2228. doi: 10.1111/dom.13354. Epub 2018 Jun 5.

PMID:
29766635
3.

Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.

Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J.

Diabetes Obes Metab. 2018 Sep;20(9):2229-2237. doi: 10.1111/dom.13363. Epub 2018 Jun 10.

PMID:
29761615
4.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Riddle MC, Bolli GB, Avogaro A, Gimenez Álvarez M, Merino-Trigo A, Boëlle-Le Corfec E, Home PD.

Diabetes Metab. 2018 Sep;44(4):333-340. doi: 10.1016/j.diabet.2017.12.001. Epub 2017 Dec 11.

5.

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.

Home PD, Ahrén B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA.

Diabetes Res Clin Pract. 2017 Sep;131:49-60. doi: 10.1016/j.diabres.2017.06.013. Epub 2017 Jun 15.

PMID:
28683300
6.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8.

7.

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD; EDITION 3 study investigators.

Diabetes Metab. 2017 Sep;43(4):351-358. doi: 10.1016/j.diabet.2017.04.007. Epub 2017 Jun 13.

9.

Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?

Giorgino F, Home PD, Tuomilehto J.

Diabetes Care. 2016 Aug;39 Suppl 2:S187-95. doi: 10.2337/dcS15-3023.

PMID:
27440832
10.

Clinical use of the co-formulation of insulin degludec and insulin aspart.

Kumar A, Awata T, Bain SC, Ceriello A, Fulcher GR, Unnikrishnan AG, Arechavaleta R, Gonzalez-Gálvez G, Hirose T, Home PD, Kaku K, Litwak L, Madsbad S, Pinget M, Mehta R, Mithal A, Tambascia M, Tibaldi J, Christiansen JS.

Int J Clin Pract. 2016 Aug;70(8):657-67. doi: 10.1111/ijcp.12821. Epub 2016 Jul 7. Review.

PMID:
27384031
11.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, Wardecki M, Vinet L, Jeandidier N, Yki-Järvinen H.

Diabetes Technol Ther. 2016 Apr;18(4):252-7. doi: 10.1089/dia.2015.0290. Epub 2016 Feb 3.

12.

Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.

Freemantle N, Danchin N, Calvi-Gries F, Vincent M, Home PD.

Diabetes Obes Metab. 2016 Feb;18(2):152-8. doi: 10.1111/dom.12598. Epub 2015 Dec 23.

13.

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX, Hu FB, Raz I, Van Gaal L, Wolfe BM, Ryan DH.

Diabetes Care. 2015 Aug;38(8):1567-82. Review.

14.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC.

Diabetes Care. 2015 Dec;38(12):2217-25. doi: 10.2337/dc15-0249. Epub 2015 Jun 17.

PMID:
26084341
15.

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

Home PD.

Diabetes Obes Metab. 2015 Nov;17(11):1011-20. doi: 10.1111/dom.12501. Epub 2015 Sep 23. Review.

16.

Biosimilar insulins: guidance for data interpretation by clinicians and users.

Heinemann L, Home PD, Hompesch M.

Diabetes Obes Metab. 2015 Oct;17(10):911-8. doi: 10.1111/dom.12491. Epub 2015 Jul 1. Review.

17.
18.

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents.

Home PD, Dain MP, Freemantle N, Kawamori R, Pfohl M, Brette S, Pilorget V, Scherbaum WA, Vespasiani G, Vincent M, Balkau B.

Diabetes Res Clin Pract. 2015 May;108(2):350-9. doi: 10.1016/j.diabres.2015.01.030. Epub 2015 Jan 23.

19.

Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.

Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD.

Diabetes Res Clin Pract. 2015 Jun;108(3):432-40. doi: 10.1016/j.diabres.2015.02.034. Epub 2015 Mar 12.

20.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators.

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

21.

Cancer and bone fractures in observational follow-up of the RECORD study.

Jones NP, Curtis PS, Home PD.

Acta Diabetol. 2015 Jun;52(3):539-46. doi: 10.1007/s00592-014-0691-y. Epub 2014 Dec 19.

PMID:
25524432
22.

A common fallacy of observational medication studies in diabetes.

Home PD.

Diabetes Obes Metab. 2015 Apr;17(4):317-8. doi: 10.1111/dom.12421. Epub 2014 Dec 23. No abstract available.

PMID:
25440575
23.

Response to comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014;37:2108-2113.

Balkau B, Home PD, Vincent M, Marre M, Freemantle N.

Diabetes Care. 2014 Dec;37(12):e266. doi: 10.2337/dc14-2152. No abstract available.

PMID:
25414401
24.

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.

Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, Carr MC.

Diabetes Obes Metab. 2015 Feb;17(2):179-87. doi: 10.1111/dom.12414. Epub 2014 Dec 10.

PMID:
25406730
25.

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.

Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2014 Sep;37(9):2647-59. doi: 10.2337/dc14-1395.

26.

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators.

Diabetes Care. 2014 Oct;37(10):2755-62. doi: 10.2337/dc14-0991. Epub 2014 Jul 30.

PMID:
25078900
27.

Response to comment on Home et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 2014;37:1237-1245.

Home PD, Shen C, Hasan MI, Latif ZA, Chen JW, González Gálvez G.

Diabetes Care. 2014 Aug;37(8):e184. doi: 10.2337/dc14-1098. No abstract available.

PMID:
25061152
28.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.

29.

Factors associated with weight gain in people with type 2 diabetes starting on insulin.

Balkau B, Home PD, Vincent M, Marre M, Freemantle N.

Diabetes Care. 2014 Aug;37(8):2108-13. doi: 10.2337/dc13-3010. Epub 2014 May 13.

PMID:
24824546
30.

Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs.

Home PD, Shen C, Hasan MI, Latif ZA, Chen JW, González Gálvez G.

Diabetes Care. 2014;37(5):1237-45. doi: 10.2337/dc13-2413. Epub 2014 Mar 4.

PMID:
24595628
31.

Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve study.

Hajjaji I, Shah S, Li Y, Prusty V, Benabbas Y, Home PD.

Diabetes Ther. 2014 Jun;5(1):113-26. doi: 10.1007/s13300-014-0052-4. Epub 2014 Jan 30.

32.

The vexed question of hypoglycaemia and health economics.

Home PD.

Diabetes Obes Metab. 2014 Apr;16(4):289-93. doi: 10.1111/dom.12266. No abstract available.

PMID:
24460874
33.

The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A₁chieve observational study.

Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z.

Diabetes Res Clin Pract. 2013 Sep;101(3):326-32. doi: 10.1016/j.diabres.2013.06.005.

34.

Validity of meta-analysis in diabetes: we need to be aware of its limitations.

Home PD.

Diabetes Care. 2013 Oct;36(10):3361-7. doi: 10.2337/dc12-2449. No abstract available.

35.

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Lopes RD.

Am Heart J. 2013 Aug;166(2):240-249.e1. doi: 10.1016/j.ahj.2013.05.004. Epub 2013 Jun 5.

36.

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.

Lopes RD, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Mahaffey KW.

Am Heart J. 2013 Aug;166(2):208-216.e28. doi: 10.1016/j.ahj.2013.05.005. Epub 2013 Jun 22.

38.

A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes.

Freemantle N, Balkau B, Home PD.

Diabetes Obes Metab. 2013 Dec;15(12):1120-7. doi: 10.1111/dom.12147. Epub 2013 Jul 16.

39.

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.

Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT.

Diabetes Care. 2013 Jun;36(6):1779-88. doi: 10.2337/dc13-0512.

40.

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.

Hall GC, McMahon AD, Dain MP, Wang E, Home PD.

Diabet Med. 2013 Jun;30(6):681-6. doi: 10.1111/dme.12137.

41.

Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease.

Hall GC, McMahon AD, Carroll D, Home PD.

PLoS One. 2012;7(11):e49908. doi: 10.1371/journal.pone.0049908. Epub 2012 Nov 14.

42.

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy.

Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, Home PD.

Obstet Gynecol Int. 2012;2012:649070. doi: 10.1155/2012/649070. Epub 2012 May 16.

43.

Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes.

Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD.

Diabetes Obes Metab. 2012 Oct;14(10):901-9. doi: 10.1111/j.1463-1326.2012.01613.x. Epub 2012 May 16.

44.

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.

Home PD.

Diabetes Obes Metab. 2012 Sep;14(9):780-8. doi: 10.1111/j.1463-1326.2012.01580.x. Epub 2012 Mar 9. Review.

PMID:
22321739
45.

Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.

Hall GC, McMahon AD, Carroll D, Home PD.

Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):305-13. doi: 10.1002/pds.2345. Epub 2012 Jan 23.

PMID:
22271442
46.

Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.

Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI.

Diabet Med. 2012 Jun;29(6):716-20. doi: 10.1111/j.1464-5491.2011.03547.x.

47.

A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes.

Hall GC, McMahon AD, Dain MP, Home PD.

Diabetes Res Clin Pract. 2011 Dec;94(3):442-8. doi: 10.1016/j.diabres.2011.09.003. Epub 2011 Oct 2.

PMID:
21963105
48.

Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.

MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ.

Diabetes Care. 2011 Jun;34(6):1394-6. doi: 10.2337/dc10-2398. Epub 2011 May 11.

49.

The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Sibal L, Agarwal SC, Home PD, Boger RH.

Curr Cardiol Rev. 2010 May;6(2):82-90. doi: 10.2174/157340310791162659.

50.

Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes.

Sibal L, Agarwal SC, Home PD.

Diabetes Metab Syndr Obes. 2011 Jan 19;4:23-34. doi: 10.2147/DMSO.S8540.

Supplemental Content

Support Center